Aldeyra Therapeutics (ALDX) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Oncology (CTOR) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 55.4% versus a loss of 83.1%. Citius Oncology is the larger company by market cap ($53.2 million vs $50.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | CTOR |
|---|---|---|
| Share price | $0.84 | $0.5035 |
| Market cap | $50.70M | $53.25M |
| 1-day change | +16.39% | -10.95% |
| YTD return | -83.78% | -49.65% |
| 1-year return | -83.06% | -55.44% |
| 5-year return | -89.06% | — |
| EPS (TTM) | $-0.31 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-33.85M | $-24.76M |
| 52-week high | $5.93 | $1.83 |
| 52-week low | $0.527 | $0.491 |
| Distance from 52-week high | -85.83% | -72.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +685.71% | +694.44% |
| Average volume | 1.16M | 114.02K |
| Shares outstanding | 60.36M | 105.76M |
| Employees | 6 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTOR has outperformed ALDX by 27.6 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
ALDX vs CTOR FAQ
Which is bigger, Aldeyra Therapeutics or Citius Oncology?
Citius Oncology (CTOR) is larger, with a market capitalization of $53.25M compared with $50.70M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or CTOR?
CTOR returned -55.44% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Citius Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.